A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models

Modification of an exposed loop in the C1 domain reduces immune responses to factor VIII in hemophilia A mice

(2012) A. Wroblewska et al.   BLOOD

Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients

(2012) J. S. Powell et al.   BLOOD

Pioneering designs for recombinant coagulation factors

(2012) Stefan Schulte   THROMBOSIS RESEARCH

Requirements for immune recognition and processing of factor VIII by antigen-presenting cells

(2011) Simon D. van Haren et al.   BLOOD REVIEWS

Polymer therapeutics as nanomedicines: new perspectives

(2011) Ruth Duncan   CURRENT OPINION IN BIOTECHNOLOGY

Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®) - an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A

(2011) U. MARTINOWITZ et al.   HAEMOPHILIA

Pharmacokinetics and pharmacodynamics of a new recombinant FVIII (N8) in haemophilia A mice

(2011) T. ELM et al.   HAEMOPHILIA

Uptake of blood coagulation factor VIII by dendritic cells is mediated via its C1 domain

(2011) Eszter Herczenik et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment

(2010) B. Mei et al.   BLOOD

Functional characteristics of N8, a new recombinant FVIII

(2010) M. L. S. CHRISTIANSEN et al.   HAEMOPHILIA

NMR structure determination of tick anticoagulant peptide (TAP)

(2010) Marguerita S.L. Lim-Wilby et al.   PROTEIN SCIENCE

PEG-modified biopharmaceuticals

(2009) Pascal Bailon et al.   Expert Opinion on Drug Delivery

Purification and characterization of a new recombinant factor VIII (N8)

(2009) L. THIM et al.   HAEMOPHILIA

A ferric chloride induced arterial injury model used as haemostatic effect model

(2009) F. MØLLER et al.   HAEMOPHILIA

Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial

(2008) J Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

The Pharmacology of PEGylation: Balancing PD with PK to Generate Novel Therapeutics

(2008) C.Simone Fishburn   JOURNAL OF PHARMACEUTICAL SCIENCES

Hemostatic effect of recombinant factor VIIa, NN1731 and recombinant factor VIII on needle-induced joint bleeding in hemophilia A mice

(2008) K. ØVLISEN et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS